The Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. An assessment by the Australian and New Zealand intensive care society.
Hicks
P
P
Cooper
D J
DJ
Webb
S
S
Myburgh
J
J
Seppelt
I
I
Peake
S
S
Joyce
C
C
Stephens
D
D
Turner
A
A
French
C
C
Hart
G
G
Jenkins
I
I
Burrell
A
A
D000925:Anticoagulants / Q000627:therapeutic use; D001315:Australia; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000502:physiology; D002316:Cardiotonic Agents / Q000627:therapeutic use; D003422:Critical Care / Q000592:standards*; D004280:Dobutamine / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D017408:Guidelines as Topic; D006801:Humans; D009520:New Zealand; D009638:Norepinephrine / Q000627:therapeutic use; D011486:Protein C / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D018570:Risk Assessment; D018805:Sepsis / Q000628:therapy*; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000925:Anticoagulants; D001786:Blood Glucose; D002316:Cardiotonic Agents; D011486:Protein C; D011994:Recombinant Proteins; D014662:Vasoconstrictor Agents; D004280:Dobutamine; D004298:Dopamine; D009638:Norepinephrine